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The p53 cancer mutation Y220C induces formation of
a cavity on the protein’s surface that can accommo-
date stabilizing small molecules. We combined frag-
ment screening and molecular dynamics to assess
the druggability of p53-Y220C and map ligand inter-
action sites within the mutational cavity. Elucidation
of the binding mode of fragment hits by crystallog-
raphy yielded a clear picture of how a drug might
dock in the cavity. Simulations that solvate the
protein with isopropanol found additional sites that
extend the druggable surface. Moreover, structural
observations and simulation revealed the dynamic
landscape of the cavity, which improves our under-
standing of the impact of the mutation on p53
stability. This underpins the importance of consid-
ering flexibility of the cavity in screening for opti-
mized ligands. Our findings provide a blueprint for
the design of effective drugs that rescue p53-Y220C.
INTRODUCTION
Mutation of the tumor suppressor p53, an essential mediator of
cellular response to oncogenic stresses, is the most frequent
genetic alteration in human cancer (Hann and Lane, 1995; Holl-
stein et al., 1991; Levine et al., 1991; Vousden and Lane,
2007). Approximately 30% of the mutations that inactivate p53
simply lower the melting temperature (Tm) of the core DNA-
binding domain of p53 (Bullock et al., 1997; Bullock et al.,
2000) so that it denatures rapidly in cells (Friedler et al., 2003).
In theory, the Tm of such a mutant, and hence its activity, can
be restored by molecules that selectively bind to its native struc-
ture and not its denatured states (Bullock and Fersht, 2001;
Joerger and Fersht, 2007). Functional studies in cells that show
temperature-sensitivemutants of p53 are transcriptionally active
at low temperatures (<37C) provide evidence that the activity of
such mutants can be rescued in a biological context (Di Como
and Prives, 1998).
The principle of p53 reactivation by small molecules was first
demonstrated using a small peptide, CDB3, which binds
reversibly to the DNA-binding domain of p53. The peptide46 Chemistry & Biology 17, 46–56, January 29, 2010 ª2010 Elsevierwas shown to stabilize wild-type and mutant p53 in vitro (Frie-
dler et al., 2002) and elevated the activity of mutant p53 in
cancer cell lines (Issaeva et al., 2003). There have been
numerous reports of other molecules that restore mutant p53
activity in cells (Bykov et al., 2002; Bykov et al., 2005; Foster
et al., 1999; North et al., 2002). However, how these molecules
reactivate p53 or, in the case of those that are known not to
bind wild-type or mutant p53 (i.e., CP-31398), induce p53-like
effects remains uncertain. It has recently been proposed that
a select group of molecules (i.e., PRIMA-1 and MIRA-1) or their
respective hydrolysis products may react covalently with p53
via modification of cysteine residues, suggesting a possible
mechanism for targeting p53 in cells (Lambert et al., 2009). It
is plausible that molecules that bind to cysteine residues in
p53 may also regulate p53 activity through modulation of the
protein’s redox state. Given the ramifications toward the devel-
opment of novel anticancer drugs, there is a fundamental need
to discover small molecules that directly stabilize temperature-
sensitive p53 mutants.
The Y220C mutation, one of the more prevalent oncogenic
mutations in p53 (associated with 75,000 new cancer cases
per annum; Joerger and Fersht, 2008; Petitjean et al., 2007),
presents an almost ideal paradigm for searching for and studying
small molecules that stabilize p53 in a mutation-specific way.
Mutation of the tyrosine to a cysteine markedly lowers the ther-
modynamic stability of the protein and, notably, induces forma-
tion of a potentially druggable cavity on the protein’s surface at
the mutation site, which is distant from the functional surface
region of the protein, without otherwise perturbing its overall
structure (Joerger et al., 2006). Hence, a small molecule could
be targeted to the mutational cavity, with the presumption that
binding, while stabilizing the protein, would not affect the func-
tion of p53. Furthermore, such a molecule would not bind to
wild-type p53 in noncancerous cells.
We recently reported the discovery of PhiKan083, a carbazole
derivative that binds to the mutational cavity of p53-Y220C,
using a simple in silico docking algorithm (Boeckler et al.,
2008). The molecule, which binds with moderate affinity
(Kd 150 mM) and also raises the Tm and slows down the rate
of denaturation of p53-Y220C, is the first such lead for mutant-
specific p53 drugs. A notable outcome of this work was that
small induced-fit movements in the protein could have large
effects on in silico predictions, which can affect the nature of
the resulting hits. This finding underpins the need for com-
plementary methods of searching for molecules that bindLtd All rights reserved
Table 1. Results of Fragment Screening of T-p53C-Y220C by
WaterLOGSY and Thermal Denaturation Scanning Fluorimetry
Variable WaterLOGSY
Thermal Denaturation
Scanning Fluorimetry
No. of fragments screened 1895 1895
No. of identified hits 205 47
No. of hits confirmed
by 15N/1H HSQC
70 17
Final hit ratio, %a 3.7 0.9
aHit ratio is defined as the ratio of the number of identified or confirmed
hits to the total number of fragments screened.
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binding site.
Here, we describe the use of fragment screening and molec-
ular dynamics (MD) simulations to further explore the druggable
surface of the p53-Y220C mutant. Specifically, we attempted to
identify all possible ligand interaction sites (i.e., ‘‘hot spots’’) on
the surface of the mutational cavity, which, collectively, provide
a blueprint for the design of molecules that bind to p53-Y220C
with druglike (submicromolar) affinity. We also sought novel
lead scaffolds with unique binding modes that expand our
present picture of how a drug could dock within the cavity.
Together, the identification of ligand binding hotspots and novel
scaffolds present the necessary basis for optimizing PhiKan083
as well as alternative starting points for drug design.
Fragment-based ligand screening has emerged as a powerful
tool for assessing the druggability of proteins and ascertaining
sites that interact with ligands (Bembenek et al., 2009; Ciulli
and Abell, 2007; Hajduk and Greer, 2007; Hajduk et al.,
2005b). This technique entails the use ofmolecules of lowmolec-
ular weight and chemical complexity to probe for areas that are
energetically favorable for ligand binding. The propensity of frag-
ment molecules to interact with a protein is indicative of whether
a protein can accommodate a molecule with druglike properties
(Hajduk et al., 2005a). Similarly, computational and experimental
methods that use organic solvents as probes can be used to
map ligand-binding sites on proteins (Dennis et al., 2002;
Liepinsh and Otting, 1997; Seco et al., 2009).
In this work, we have screened the core domain of p53-Y220C
against a fragment library by water-ligand-observed-gradient
spectroscopy (waterLOGSY) and thermal denaturation scanning
fluorimetry. Fragment binding was subsequently confirmed by
heteronuclear single-quantum coherence (15N/1H HSQC) NMR.
The binding mode of several fragments was solved by X-ray
crystallography. Moreover, MD simulations have been used to
probe the dynamic properties of the mutational cavity and the
preferential binding modes of isopropanol, which mimics a
small-molecule drug.
RESULTS AND DISCUSSION
Fragment Screening
Ligand-binding sites on T-p53C-Y220C, a stable variant of p53
core domain (Joerger et al., 2004; Nikolova et al., 1998) with
the Y220C mutation, were initially explored by screening against
a chemically diverse fragment library. The library of nearly 1900
molecules was designed according to the generalized rule-of-
three for the physicochemical properties of fragments (Congreve
et al., 2003). To minimize the number of false-positive and false-
negative results (fragments that bind T-p53C-Y220C but are not
detected), two parallel methods including waterLOGSY, a one-
dimensional ligand-observed NMR method, and thermal dena-
turation scanning fluorimetry, which scans the effect of a ligand
on the Tm of a protein using an exogenous fluorescent dye, were
used for screening.
Screening bywaterLOGSY and thermal denaturation scanning
fluorimetry found 205 and 47 fragment hits against T-p53C-
Y220C, respectively (Table 1). Of the hits identified by thermal
denaturation scanning fluorimetry, the maximum observed
shift in Tm was 1.8 ± 0.2
C. Binding of the fragment hits fromChemistry & Biology 17,both methods was subsequently confirmed by 15N/1H HSQC,
which iswidely considered themost definitive assay for detecting
protein-ligand binding interactions (Hajduk et al., 2005b). The
final hit rates forwaterLOGSYand thermal denaturation scanning
fluorimetry, considering only the fragments forwhich bindingwas
confirmed, were 3.7% and 0.9%, respectively. Comparison of
the hit rates indicates that a large number of fragment hits were
missed by thermal denaturation scanning fluorimetry. A likely
cause of false-negative results in this assay is fluorescence
quenching by the fragment molecules. Additionally, analysis of
the hit rate provides an estimate of the druggability of T-p53C-
Y220C, as suggested by Hajduk et al. (2005a). The combined
hit rate is only marginally lower than the reported threshold value
for proteins for which high-affinity ligands have been developed.
Analysis of the final fragment hits, of which there were 84 in
total, found a number of structural similarities. These similarities
constitute pharmacophore features that can be used to classify
the fragment hits. The fragments could be classified in seven
unique families, as shown in Figure 1. Among the key pharmaco-
phore features that differentiate the families are the number of
rings in the central scaffold as well as the spacing between rings
when there is more than one, aromaticity of the ring system,
number of molecules in each ring, and the size of attached
substituent groups. Molecule 14 was found to have the tightest
binding affinity (Kd = 105 ± 12 mM) of the confirmed hits. Although
it is difficult to predict the implications of the distinctive structural
features with respect to possible interactions formed between
the fragments and protein, it is highly likely that the ring system
of the respective fragments mimics the side chain of themutated
tyrosine, packing between the hydrophobic residues that line the
cavity (Joerger et al., 2006).
Thermal denaturation scanning fluorimetry represents a rela-
tively new biophysical technique for fragment screening (Ciulli
and Abell, 2007). Despite growing interest in this technique for
screening, there is little data on its utility in measuring weak
binding affinities, which are characteristic of fragments. To the
best of our knowledge, this report is the first direct comparison
of thermal denaturation scanning fluorimetry and NMR, a
conventional tool for assaying ligands with a broad range of
binding affinities, for fragment screening. Of the confirmed hits,
17 were found from thermal denaturation scanning fluorimetry
and 70 from waterLOGSY. Interestingly, only three of the hits
were identified in both assays, indicating that the overlap of hits
from the respective methods was low. These fragments do not
share any obvious structural similarities from which conclusions
can be drawn about why they were identified in both assays or,46–56, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 47
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Figure 1. Pharmacophore Classification of Confirmed Fragments Hits
The fragment hits were classified on the basis of chemical structure. Representative structures of each classification are presented and separated accordingly.
The fragment hits whose binding modes to T-p53C-Y220C were solved via X-ray crystallography are indicated in bold and underlined.
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Probing the Surface of the Oncogenic Y220C Mutantmore importantly, why binding of the fragmentswas not detected
in both assays. The screening results clearly show that, although
thermal denaturation scanning fluorimetry is not as sensitive as
waterLOGSY (i.e., has a higher rate of false negatives), it can
potentially still generate unique hits and thus can be useful as
a complementary fragment screening technique.
Identification of Target Binding Site of Fragment Hits
Analysis of ligand binding by 15N/1HHSQCprovides site-specific
resolution of the binding surface on the protein. The target
binding site can be inferred from mapping chemical shifts in
resonances of residues that are perturbed upon binding (Meyer
and Peters, 2003). Because T-p53C-Y220C is a highly destabi-
lized protein, only a partial resonance assignment was obtain-
able from analogy with wild-type p53, where peaks overlaid,
and limited triple resonance NMR data of the mutant protein.
Unfortunately, resonances close to themutation site differ signif-
icantly from those in the spectra of wild-type, and these were
most difficult to assign with the required certainty.
Qualitative analysis of chemical shifts in 15N/1H HSQC spectra
of T-p53C-Y220C in complex with the fragment hits found48 Chemistry & Biology 17, 46–56, January 29, 2010 ª2010 Elseviermultiple peak perturbations (Figure 2). Residues Val147 and
Asp148, both of which are positioned in the central region of
the cavity, are among those clearly disturbed by each of the
confirmed fragment hits (Figure 2; lower panels). In the spectra
for many of the fragment hits, residues Tyr107, Thr155, and
Ser260, all of which are also in the cavity region, are also shifted.
Perturbations of these residues, coupled with the observation
that assigned residues outside the cavity are unaffected by
binding, implies that the fragments bind exclusively to the cavity
region. A number of other prominent shifts in peaks that were not
assigned, but thought to be of residues in the cavity region,
further support the conclusion that the fragments bind to the
mutation site. Because of the absence of disturbances at other
sites on the protein, it can be further inferred that wild-type
p53 is a very challenging target, consistent with structural obser-
vations showing it lacks pronounced surface crevices and that
only p53 mutants with altered surface properties (but unper-
turbed DNA-contact surfaces) are candidate drug targets.
Consistent with this, a screen of wild-type p53 core domain
(T-p53C) by waterLOGSY and thermal denaturation scanning
fluorimetry did not find any fragment hits. Additionally,Ltd All rights reserved
10
10
9
9
8
8
7
7
ω 2 - 
1H  (ppm)
135 135
130 130
125 125
120 120
115 115
110 110
105 105
ω
1 
-
 
15
N
  (p
pm
)
7.85
7.85
7.80
7.80
7.75
7.75
7.70
7.70
7.65
7.65
111.0 111.0
110.5 110.5
110.0 110.0
109.5 109.5
Val147
9.10
9.10
9.05
9.05
9.00
9.00
8.95
8.95
8.90
8.90
122.5 122.5
122.0 122.0
121.5 121.5
121.0 121.0
Asp148
ω 2 - 
1H  (ppm)ω 2 - 1H  (ppm)
ω
1 
-
 
15
N
  (p
pm
)
ω
1 
-
 
15
N
  (p
pm
)
Val147
Asp148
Thr155
Ser260
Tyr107
Figure 2. Overlay of 15N/1H HSQC Spectra of T-p53C-
Y220C
Shown are T-p53C-Y220C alone (red) and T-p53C-Y220C in
the presence of fragments 2 (1 mM; blue), 3 (1 mM; cyan),
4 (1 mM; orange), 11 (1 mM; green), and 15 (1 mM; purple).
Resonances for residues Val147, Asp148, Tyr107, Thr155,
and Ser260, which are in or near themutational cavity, are indi-
cated. The lower panels show magnified views of spectral
changes to residues Val147 and Asp148 upon addition of the
fragments.
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peaks between spectra suggest the fragments may bind with
different binding modes. However, the exact positioning and
overall orientation of the molecules in the binding pocket cannot
be determined from analysis of 15N/1H HSQC data alone and
requires the use of structure determination methods.
Structural Determination of Fragment-Binding Modes
In an attempt to elucidate the binding mode of all confirmed
fragment hits, crystals of T-p53C-Y220C were soaked with the
individual fragments and structures of the resulting protein-
ligand complex determined by X-ray crystallography. Because
of low occupancy of the fragments within the cavity and disrup-
tion of the crystal packing upon fragment binding, structural
elucidation of the binding mode was possible only for a small
subset of the confirmed fragments hits (Figure 1). The resolution
of the solved complex structures was in the range of 1.6–2.1 A˚
(see Table 2 for data collection and refinement statistics).
An electron density map for fragment 15 is shown in Figure S1
available online. In all structures, the small molecule occupied
only one of the two molecules in the asymmetric unit
(chain B), which is consistent with our earlier data (Boeckler
et al., 2008).
The general binding mode of fragments 2, 11, and 15 involves
sandwiching of the ring systems between Pro151 and Val147 onChemistry & Biology 17, 46–56, Januaone side of the cavity and Pro222 and Pro223 on
the other (Figures 3A–3C). As a result of binding,
the sulfhydryl group of the mutated Cys220 residue
at the bottom of the cavity is displaced, thus deep-
ening the pocket by 2 A˚ and, in turn, allowing
accommodation of the ligands. This flip of the
cysteine side chain triggers a concerted movement
in two hydrophobic side chains (Val157 and Ile232)
in the interior of the protein. Additionally, shifts in
a number of residues around the periphery of the
cavity (e.g., Thr150 and Pro222) are observed
upon binding, which are indicative of the flexibility
of the cavity.
The structure of fragment 15 bound to T-p53C-
Y220C (solved at 1.6 A˚ resolution) shows that the
molecule sits deeply within the mutation-induced
cavity (Figure 3A). The sulfur atom on the thiazole
ring is positioned near the mutated Cys220 residue
at the deepest part of the cleft. In addition to hydro-
phobic packing interactions, fragment 15 forms
specific hydrogen bonds with the protein and
water molecules. Most significantly, the substituentamine in the 2-position on the thiazole ring makes a hydrogen
bondwith the carbonyl oxygen of Leu145 and a conserved water
molecule that bridges the amine with the main chain of Asp228.
As such, it occupies the position of a water molecule in the
ligand-free structure that is displaced upon binding. The thiazole
nitrogen and oxygen of the dioxane ring are also involved in
water-mediated hydrogen bonds.
Fragment 11, which also contains an aromatic benzothiazole
ring system, binds in the same plane as fragment 15 within the
cavity but sits in a more upright position (Figure 3B). Positioned
as such, the thiazole nitrogen is within hydrogen-bonding
distance of the hydroxyl group of Thr150. The methoxy moieties
of the molecule sit at the bottom of the cavity in close proximity
to Cys220.
The binding mode of fragment 2 (determined at 1.8 A˚ resolu-
tion) is unique in that two molecules are bound within the cavity
(Figure 3C). The molecules are positioned at opposite sides of
the cavity with the trifluoromethyl groups of each pointing toward
the mutated Cys220 residue. Binding of molecule a is stabilized
by the interaction of the amine at position 2 on the aromatic ring
with the carbonyl oxygen of Leu145 and a conserved water
molecule, thus mimicking the binding mode of the amino group
in fragment 15. The amines at positions 1 and 2 are both involved
in a network of hydrogen-bond interactions with water mole-
cules. Molecule a makes hydrophobic interactions with Val147ry 29, 2010 ª2010 Elsevier Ltd All rights reserved 49
Table 2. Data Collection and Refinement Statistics for T-p53C-Y220C Ligand Structures
Variable Fragment 15 Fragment 11 Fragment 2
Data collection
Space group P212121 P212121 P212121
Cell, a, b, c, A˚ 65.06, 71.14, 105.41 65.25, 70.58, 105.44 65.23, 71.09, 105.39
Molecules/ASU 2 2 2
Resolution, A˚a 35.5–1.60 (1.69–1.60) 35.5–2.10 (2.21–2.10) 41.1–1.80 (1.90–1.80)
Unique reflections 65,261 29,108 45,419
Completeness, %a 99.9 (100) 99.9 (100) 98.7 (97.9)
Multiplicity a 6.2 (5.8) 3.5 (3.6) 3.7 (3.7)
Rmerge, %
a,b 7.0 (31.1) 10.8 (29.4) 6.3 (22.4)
< I/sI >
a 15.8 (5.2) 8.6 (4.1) 14.2 (5.5)
Wilson B value, A˚2 13.8 15.4 14.0
Refinement
No. of atoms
Proteinc 3105 3080 3089
Water 656 523 601
Ligand 14 14 24
Zinc 2 2 2
Rcryst, %
d 16.5 17.2 15.9
Rfree, %
d 19.3 22.8 19.0
Rmsd bonds, A˚ 0.007 0.007 0.008
Rmsd angles,  1.12 1.0 1.14
Mean B value, A˚2 17.3 16.6 17.1
Ramachandran statisticse
Allowed/favored, % 100/99.5 100/99.0 100/99.5
aData in parentheses are for the highest resolution shell.
b Rmerge =
P
(Ih,i  < Ih >)/
P
Ih,i.
c Number includes alternative conformations.
d Rcryst and Rfree =
PkFobsj  jFcalck/
PjFobsj where Rfree was calculated over 5% of the amplitudes chosen at random and not used in the refinement.
e Calculated with MOLPROBITY (Davis et al., 2007).
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fragments 15 and 11, whereas molecule b packs between the
hydrophobic side chains of Pro153 and Pro222 at a site that
is not occupied by the other fragments. The fluorine atoms
likely play a significant role in binding by coordinating strongly
with the protein. Moreover, the fluorine atoms can indirectly
strengthen the binding interaction of the fragment by polarizing
the amine groups attached to the benzene ring. The fluorination
of leadlike molecules canmarkedly enhance their binding affinity
and overall biological activity (Bohm et al., 2004).
Structuresof T-p53C-Y220C incomplexwith fragments3and4
were also solved; however, only partial electron density for
the fragments was observed (data not shown). Consequently,
the exact binding mode of the fragments within the cavity could
not be unambiguously modeled. The parts of the fragments
that showed the clearest density were the aromatic rings,
which were positioned between Pro151 and Pro222, suggesting
their bindingmodesweresimilar to that of fragments2, 11,and15.
MD Simulations of T-p53C-Y220C Solvation
by Isopropanol
Seco et al. (2009) previously demonstrated the possibility to
identify drug-binding sites and protein-protein interaction inter-50 Chemistry & Biology 17, 46–56, January 29, 2010 ª2010 Elsevierfaces on proteins of pharmacological interest using MD simula-
tions of proteins in mixtures of water and isopropanol. Similarly,
Guvench and MacKerell (2009) used MD simulations of the
protein BCL-6 in solutions of organic solvents in water to map
the affinity of hydrophobic and aromatic molecules on the pro-
tein’s surface. Using the simulation results, the authors were
able to accurately predict the binding mode of two peptide
substrates, which was confirmed by X-ray crystallography. To
explore further the druggable surface of T-p53C-Y220C, we
determined the preferential solvation of the protein by MD
simulation with isopropanol (20% v/v). In the simulation, isopro-
panol represents a theoretical ligand with polar and nonpolar
properties that can bind to T-p53C-Y220C via hydrogen bonding
and hydrophobic interactions.
Over the time course of the simulation, the MD trajectory of
T-p53C-Y220C remained close to the x-ray structure (backbone
RMSD 1.5 A˚). Analysis of the resulting isopropanol density iso-
surface of T-p53C-Y220C found several regions of high density
of isopropanol. The area of highest density of isopropanol was
found on the surface that forms the self-complementary core
domain-core domain interface upon binding to a DNA half-site
(Kitayner et al., 2006) and a surface patch around Leu188 and
Leu201. However, because only the site of the mutation provedLtd All rights reserved
AB
C
C220
C220
C220
C220
C220
C220
T150
T150
T150
T150
T150
P153
P153
P153
P153
P153
P153
L145
L145
L145
L145
L145
L145
D228
D228
D228
D228
D228
D228
T150
a
b
a
b
Figure 3. Binding Mode of Lead Fragments in
the Mutation-Induced Cavity of T-p53C-Y220C
(A–C) Stereo view of the Y220C cavity with bound frag-
ments 15 (A), 11 (B), and 2 (C) is shown. In all three
cases, the fragment-bound structure (green) is super-
imposed onto the structure of the ligand-free mutant
(PDB code 2J1X; gray). Polar contacts of fragments
with the protein and water molecules (red spheres)
are shown as dashed lines.
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Probing the Surface of the Oncogenic Y220C Mutantto bind small molecules, as was evident by the fragment
screening, we focused our analysis solely on this site.
The density of isopropanol in the mutation-induced cavity
was more than four times higher than the expected value for
the bulk mixture, indicating the propensity of solvent binding
in the pocket. Localization of isopropanol molecules within
the cavity between Pro153, Pro222, and Cys220 was observed
(Figure 4A). The hydroxyl group of isopropanol made hydrogen
bonds with the backbone carbonyl oxygen of Pro151 and
Pro152. The estimated binding free energy associated with
the interaction of isopropanol at this site is 3.9 kcal/mol, as
calculated with the procedure proposed by Seco et al. (2009).
Conversely, the area of the cavity between the side chains of
Val147, Pro151, and Pro223, corresponding to the area occu-
pied by the aromatic ring system of the bound fragments,
was devoid of isopropanol molecules. The absence of isopro-
panol in this area can presumably be attributed to the avail-
able space of the cavity, which cannot accommodate isopro-
panol molecules in an energetically favorable configuration.
Importantly, differences in the chemical nature of isopropanol
and the cyclic fragment molecules allowed us to explore
distinctly different binding sites using isopropanol as a molec-
ular probe.Chemistry & Biology 17, 46–56, January 29,In addition to yielding solvation patterns of
isopropanol on T-p53C-Y220C, the MD
simulation illuminates how structural motions
in the cavity may affect ligand binding. Anal-
ysis of the cavity dynamics found that the
width of the region where isopropanol binds
is highly flexible. Fluctuations in the side
chain of Pro222, in particular, greatly altered
the cavity width. The distance between the
Ca of Pro153 and the Cg of Pro222 ranged
from 5-9 A˚ over the time-course of the simu-
lation (Figure 4B). During the initial 3 ns, when
isopropanol molecules occupy the cavity,
the cavity width at this point varied between
7 A˚ and 9 A˚, which matches that observed
in the crystal structures of the free and frag-
ment-bound protein. In the absence of iso-
propanol, the cavity fluctuated between an
apparent open and closed state, where the
distance between the defined points was
5–7 A˚. Dynamic fluctuations in the width of
the cavity are likely to dictate the accessi-
bility of the cavity to a ligand. The depth of
the cavity, defined by the distance between
the sulfur atom of Cys220 and the Ca ofPro222, also fluctuated within a range comparable to that
observed in the crystal structures (Figure 4B). The cavity depth
was altered significantly only when isopropanol was within the
cavity, suggesting an induced-fit phenomenon. At present,
whether the induced-fit movements of the cysteine upon ligand
binding have an associated energetic penalty remains unclear.
In this context, it is interesting to note that this cysteine flip
was not observed upon binding of PhiKan083 (Boeckler et al.,
2008).
Mutations that lead to increased atomic fluctuations have
been linked to the instability of proteins (Interlandi et al., 2008).
Our structural and MD observations reveal the cavity region of
p53-Y220C to be highly dynamic. To determine whether binding
of the fragments alters the plasticity of the cavity, we investi-
gated the dynamics of T-p53C-Y220C in complex with the frag-
ments using Gaussian network model (GNM) analysis (Yang
et al., 2006). The GNM represents the protein as an elastic
network where harmonic springs connect neighboring nodes
(distance <10 A˚) centered on the Ca-atoms of residues in the
native structure. The GNMhas been shown to be highly accurate
in reproducing experimental data on structural fluctuations of
biological macromolecules (i.e., crystallographic B-factors and
H/D exchange protection factors) (Bahar et al., 1997; Bahar2010 ª2010 Elsevier Ltd All rights reserved 51
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p53 (black line), free T-p53C-Y220C (red line) and T-p53C-Y220C bound to
fragments 15 (green), 11 (blue) and 2 (magenta) determined by Gaussian
network modeling. A 10 A˚ cutoff for amino acid pairs (Ca-Ca) was used in
the analysis.
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Probing the Surface of the Oncogenic Y220C Mutantet al., 1998) and has been widely used to study the functional
consequence of those fluctuations (Bahar et al., 1999; Tobi
and Bahar, 2005). In the context of the GNM, the presence of
the fragments in themutational cavity is introduced by extending
the model’s elastic network to include select atoms of the frag-
ments. Protein-fragment interactions are therefore assigned
with the same nonspecific character as protein-protein interac-
tions. Accordingly, such interactions are dependent only on the
size and position of the fragments within the pocket and do not
account for the chemical nature of the fragments.
Results of the GNM analysis (Figure 5) found that the presence
of the fragments markedly reduces the flexibility of the cavity
region. The backbone dynamics of T-p53C-Y220C in the cavity
upon binding of the fragments are virtually identical to that of
wild-type p53 core domain. The fragments presumably couple
the proline-rich loops that line the mutational cavity to the rest
of the protein, thus enhancing the rigidity of the region. The loops
in T-p53C-Y220C in the absence of fragments are, instead, loose
and very flexible, highlighting the importance of the tyrosine ring
system in the wild-type protein in holding the proline-rich loops
together, thereby stabilizing the local structure. This result is
supported by the observation that Pro222 exhibits significantly
reduced temperature factors in the crystal structures of all
Y220C-ligand complexes compared with the structure of the
ligand-free mutant.
Implications for Rescue of p53-Y220C
The binding sites of the fragments partly overlap with that of
PhiKan083 (Figure 6). In the Y220C-PhiKan083 complex, the52 Chemistry & Biology 17, 46–56, January 29, 2010 ª2010 Elsevier Ltd All rights reservedN-ethyl substituent of the central carba-
zole ring system serves as a hydrophobic
anchor, occupying the deepest part of the
binding pocket, next to the sulfhydryl
group of Cys220 (Boeckler et al., 2008).
The cysteine flip observed upon binding
of fragment 15 further extends the cavity
depth as a result of the benzothiazole
ring system sitting much deeper in the
pocket than the carbazole ring system of
PhiKan083 (Figure 6A). Consequently,
Thr150 at the upper rim of the binding
pocket sits closer to the center of thecavity compared with Phikan083. The fragments also address
parts of the cavity, next to Pro153, that are not occupied by Phi-
Kan083. On the other hand, the protonatedmethanaminemoiety
of PhiKan083 is hydrogen-bonded to the main-chain oxygen of
Asp228, at a site of the cavity that is not occupied by the
fragments.
The results of fragment screening and MD have considerable
implications toward the rational design of lead ligands that stabi-
lize p53-Y220C. When taken together, the collection of frag-
ment-binding modes and preferential sites of isopropanol
C220 C220
T150
L145L145
D228D228
T150
P153 P153
A
B
Figure 6. Overlay of Lead Fragment Hits
(A) Stereo view of the structure of T-p53C-Y220C
(gray) in complex with the benzothiazole-based frag-
ment 15 (beige) superimposed onto the structure of
T-p53C-Y220C (cyan) bound to Phikan083 (green)
(PDB code 2VUK) (Boeckler et al., 2008).
(B) Overlay of lead fragment hits from this study, Phi-
kan083, and density of isopropanol oxygen (red) and
carbon (blue) atoms in the cavity of T-p53C-Y220C
from MD simulations contoured at four times the
density of the bulk mixture. The superposition is based
on the complete B chain of all structures. Protein
atoms are omitted for clarity. The color code of the
fragments is the same as in Figure 3 with PhiKan083
shown in green. Two views are shown: side view
(upper panel) and view from the top of the cavity after
90 rotation around the x-axis (lower panel).
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mutational cavity. Importantly, the overlay of the fragments and
isopropanol-binding sites fill the cavity completely, thereby
revealing a multitude of interaction points on the cavity surface
(Figure 6B). Using this information, the binding efficiency of the
fragment hits can, in principle, be improved by either enlarging
the constituent fragments to incorporate adjacent interac-
tion sites or tethering fragments with complementary binding
modes. The structure of T-p53C-Y220C with two molecules of
fragment 2 bound at different sites illustrates nicely how frag-
ments with different binding modes can be linked to encompass
multiple interaction sites (Figure 3C). The binding free energy
of an optimized ligand should be the sum of the energies of
the individual subsites, enhanced by an entropy term (the
‘‘chelate effect’’) (Horovitz and Fersht, 1992) and negated by
any unfavorable energetic penalties imposed by the linkers
(Erlanson, 2006).
Our understanding of the structural plasticity of the cavity
region can also aid in the design of lead ligands with improved
binding affinities. Conformational changes in the cavity can
significantly alter the cavity geometry and, in turn, the orientation
of ligand interaction sites with respect to one another. Intro-
ducing flexible regions into the ligand increases the likelihood
the ligand can adapt to the plasticity of the target binding site.
The incorporation of flexibility in ligand design is reminiscent of
the strategy used to circumvent mutation resistance that stems
from changes in binding-site structure (Das et al., 2008; Teague,
2003). In addition, flexibility may be incorporated into computa-
tional approaches for ligand design.Chemistry & Biology 17, 46–56, January 29,SIGNIFICANCE
The tumor suppressor p53, a key protein
in safeguarding cells from growing
unchecked, is widely mutated in human
cancers. Small molecules that bind to
and rescue the function of mutant p53
thus have broad implications as anti-
cancer therapeutics. The p53 cancer
mutation Y220C, which destabilizes p53,
presents a unique opportunity to target
mutant p53. The mutation induces forma-tion of a surface cavity that can accommodate stabilizing
small molecules. Our results paint a clear picture of how
a druglike molecule could dock within the mutational cavity
of the Y220C mutant. Specifically, we have mapped ligand-
binding sites in the mutational cavity of p53-Y220C using
fragment screening and MD. The combination of fragment-
based screening and MD simulation, as exemplified here,
could, more broadly, be applied to map key interaction sites
in novel targets. Structural elucidation of the binding modes
of several of the fragments shows, with atomistic detail, the
interactions responsible for stabilizing the fragment in the
cavity region. Moreover, observation of the dynamic land-
scape of the cavity region highlight the relationship between
protein flexibility and stability. The fragment hits, as shown
by MD, markedly reduce the backbone dynamics of T-p53-
Y220C in the cavity region, thus stabilizing the protein’s local
structure. Ultimately, these finding provide the framework
for the rational design of lead ligands that rescue the tran-
scriptional activity of the oncogenic p53-Y220C by selec-
tively targeting the mutation site.
EXPERIMENTAL PROCEDURES
Fragment Library
Fragments were purchased from Chembridge (San Diego, CA), Life Chemicals
(Kiev, Ukraine), and Maybridge (Cornwall, United Kingdom).
Protein Expression and Purification
The T-p53-Y220C protein, containing p53 residues 94–312, was produced
following the procedure described for wild-type p53 (Boeckler et al., 2008).2010 ª2010 Elsevier Ltd All rights reserved 53
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fication. For 15N/1H HSQC experiments, the protein was expressed in M9
minimal media with 15NH4Cl as the only nitrogen source. For crystallization,
a tag-free form of the protein was produced and purified.
Fragment Screening by Thermal Denaturation Scanning Fluorimetry
The effect of ligands on the Tm of T-p53C-Y220Cwasmonitored via high-reso-
lutionmelt analysis using a Corbett (Mortlake, Australia) Rotor-Gene 6000 real-
time PCR thermocycler. Briefly, the protein (15 mM)wasmixedwith the fluores-
cent dye SYPRO orange (Invitrogen, CA; diluted 1000-fold) in buffer (25 mM
potassium phosphate, 150 mMNaCl, and 5 mM DTT [pH 7.5]) with 1 mM frag-
ment, which was added from 20 mM stock solutions in neat DMSO (5% v/v
final concentration). Fluorescence of the dye was measured continuously
while ramping the temperature from 30 to 50C at a rate of 0.1C/s using exci-
tation and emission filters of 460 and 510 nm, respectively. The Tm of the
protein with the addition of fragment was determined from the derivative of
the fluorescence versus temperature curve and was compared to control
samples consisting of protein with DMSO only. All samples were measured
in triplicate. Fragments that raised the Tm of the protein by 0.5
C or greater
were considered hits.
Fragment Screening by WaterLOGSY
WaterLOGSY experiments were performed at 20C on a Bruker DRX500 spec-
trometer (500 MHz 1H frequency) equipped with a 5-mm inverse cryogenic
probe head. Fragments were screened in mixtures of five, at an individual
concentration of 300 mM in 25 mM sodium phosphate and 150 mM NaCl
(pH 7.2) with 5% v/v DMSO-d6. Ligand binding was identified by the decrease
or reversal in intensity of the ligand signal in the presence of protein. Because
the ligand mixtures were designed to avoid resonance overlap between the
difference components, additional deconvolution of mixtures of hits was not
necessary. All spectra were recorded with an NOE mixing time of 900 ms
and a recycle delay of 2.5 s. For each individual spectrum, 128 transients
were acquired with 4096 time domain data points, covering a spectral width
of 6.0 kHz (centered on resonance for water).
15N/1H HSQC Analysis of Fragment Binding
15N/1H HSQC spectra of T-p53-Y220C (75 mM) were acquired at 20C on
a Bruker Avance-800 spectrometer (800 MHz 1H frequency) using a 5-mm
inverse cryogenic probe. Samples were prepared by adding ligand (1 mM)
to buffer (25 mM sodium phosphate, 150 mM NaCl, and 5 mM DTT [pH 7.2])
with 5% (v/v) DMSO-d6. Using the criteria for hit identification defined by Haj-
duk et al. (1997), the minimum threshold for significant perturbations in 15N or
1H nuclei was 0.1 ppm.
Crystallographic Determination of Fragment-Binding Mode
Crystals of T-p53C-Y220C were grown via the sitting drop vapor diffusion
method, as described elsewhere (Joerger et al., 2006). They were soaked in
solutions of fragment (100 mM or saturated solution) in cryo buffer (19% w/v
polyethylene glycol 4000, 20% v/v glycerol, 10 mM sodium phosphate
[pH 7.2], 100mMHEPES [pH 7.2], 150mMKCl, and 10mMDTT) for aminimum
of 6 hr and flash frozen in liquid nitrogen. X-ray data sets were collected at
100 K at the Diamond Lights Source, Oxford (beamline I02), and the ESRF,
Grenoble (beamlines ID14-1 and ID14-2). All data sets were processed with
MOSFLM (Leslie, 1999) and SCALA (Evans, 2006). The structure was solved
by rigid body refinement with PHENIX (Adams et al., 2002) using the structure
of the ligand-free mutant (PDB ID 2J1X) as starting model. After an initial round
of refinement, water molecules were added to the structures using PHENIX.
The fragments were then manually built into the structure using MAIN
(Turk, 1992), and the resulting models were further refined with PHENIX.
Data collection and refinement statistics are shown in Table 2.
MD Simulations
Simulations of the T-p53-Y220C mutant (PDB ID 2VUK chain A), explicitly
solvated in a mixture of isopropanol (20% v/v) and water, were computed
using the CHARMM (Brooks et al., 1983) and NAMD (Phillips et al., 2005)
programs and the param22 all-atom force field (MacKerell et al., 1998) for
a productive trajectory of 19 ns. Details of the simulation protocol are reported
in the Supplemental Information.54 Chemistry & Biology 17, 46–56, January 29, 2010 ª2010 ElsevierAnalysis of the trajectories was performed using WORDOM (Seeber et al.,
2007), VMD (Humphrey et al., 1996), and the GROMACS analysis tools
(Hess et al., 2008). The procedure for determining solvation and druggability
was described previously by Seco et al. (2009) and is summarized in the
Supplemental Information.
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